These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 21035633)

  • 1. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
    Boulenger JP; Hermes A; Huusom AK; Weiller E
    Curr Med Res Opin; 2010 Mar; 26(3):605-14. PubMed ID: 20067433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B; Andersen HF; Dolberg OT
    Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP; Tonnoir B; Ménard F; Galinowski A
    Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escitalopram therapy for major depression and anxiety disorders.
    Baldwin DS; Reines EH; Guiton C; Weiller E
    Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
    Daléry J; Aubin V
    Encephale; 2001; 27(1):71-81. PubMed ID: 11294041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of escitalopram and paroxetine in the treatment of major depressive disorder.
    Lin HL; Hsu YT; Liu CY; Chen CH; Hsiao MC; Liu YL; Shen WW; Hsiao CF; Liu SI; Chang LH; Tang HS; Lai HL; Lin PS; Lin KM; Tsou HH
    Int Clin Psychopharmacol; 2013 Nov; 28(6):339-45. PubMed ID: 23881184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of escitalopram on sleep problems in depressed patients.
    Lader M; Andersen HF; Baekdal T
    Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.